Carnot institutes

CEA LETI & CEA LIST participate in the Consumer Electronic Show (CES) with three spin-off start-ups

For this 100% digital version, the CEA is supporting 3 spin off start-ups from its laboratories that have developed technological solutions in response to three major societal challenges: 

  • The energy transition, with Wise-Integration, which will present the world's smallest charger for electric bicycles,

  • The digital transition with Alkalee, which has developed a software suite equipped to bring agility and openness to the vehicles of tomorrow,

  • And the health of the future, with iUMTEK for rapid quantitative and qualitative diagnosis of air pollution

Institut Curie (Curie Cancer Carnot Institute) & Google initiate a collaboration using artificial intelligence (AI) for the analysis of complex data

Institut Curie (Curie Cancer Carnot Institute) and Google initiate a joint artificial intelligence research program to develop and implement deep learning methods for the analysis of complex single-cell transcriptomic and epigenetics data. Obtained from mouse samples and cell lines, these valuable data sets will be used to develop new deep-learning algorithms. In the long term, this research project could help characterize the heterogeneity of tumors and predict resistance to treatment.

Ibex Medical Analytics & Institut Curie (Curie Cancer Carnot Institute) partner to improve AI-powered breast cancer detection

Institut Curie (Curie Cancer Carnot Insitute) and Ibex Medical Analytics, a pioneer in artificial intelligence based cancer diagnostics, announce a research partnership aimed at improving diagnosis of breast cancer with Artificial Intelligence

Owkin and CALYM Carnot Institute Launch a Collaboration to Advance Lymphoma Research with Artificial Intelligence

Owkin, a startup that deploys AI and Federated Learning technologies to augment medical research and enable scientific discoveries, announces a collaboration with Lymphoma research consortium Institut Carnot CALYM. This engagement was formed to leverage high-quality datasets from LYSARC, member of Institut Carnot CALYM, as well as Owkin’s pioneering technologies and research platform, to advance clinical research and drug development for the benefit of patients.

Pages